drugset / Trial / NCT05029141
New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Phase 2
Active not recruiting
21 enrolled
The First Affiliated Hospital of Soochow University
Anhui Provincial Hospital · collabFirst Affiliated Hospital of Harbin Medical University · collabFujian Medical University Union Hospital · collabNanfang Hospital, Southern Medical University · collabQilu Hospital of Shandong University · collabRuijin Hospital · collabShandong Provincial Hospital · collabThe First Hospital of Jilin University · collabWest China Hospital · collabXinqiao Hospital of Chongqing · collabZhengzhou University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is to investigate the therapeutic efficacy and side effect of chidamide, azacitidine combined with priming HAG regimen for relapsed or refractroy acute myeloid leukemia
Timeline
- Start
- 2021-09-01
- Primary completion
- 2026-12-31
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tucidinostat | Small molecule | 30 mg | Oral |
| Background | Azacitidine | Other / unclassified | 75 mg/m2 | Intravenous |
| Background | Cytarabine | Small molecule | 10 mg/m2 | Subcutaneous |
| Background | Homoharringtonine | Small molecule | 1 mg/m2 | Intravenous |